FCCC LOGO Faculty Publications
Borghaei H , Gettinger S , Vokes EE , Chow LQM , Burgio MA , de Castro Carpeno J , Pluzanski A , Arrieta O , Frontera OA , Chiari R , Butts C , Wójcik-Tomaszewska J , Coudert B , Garassino MC , Ready N , Felip E , García MA , Waterhouse D , Domine M , Barlesi F , Antonia S , Wohlleber M , Gerber DE , Czyzewicz G , Spigel DR , Crino L , Eberhardt WEE , Li A , Marimuthu S , Brahmer J
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer
J Clin Oncol. 2021 Mar 1;39(7) :723-733
PMID: 33449799    PMCID: PMC8078445    URL: https://www.ncbi.nlm.nih.gov/pubmed/33449799
Back to previous list
Abstract
PURPOSE: Immunotherapy has revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in overall survival (OS) and favorable safety versus docetaxel in patients with previously treated, advanced squamous and nonsquamous NSCLC, respectively. We report 5-year pooled efficacy and safety from these trials. METHODS: Patients (N = 854; CheckMate 017/057 pooled) with advanced NSCLC, ECOG PS ≤ 1, and progression during or after first-line platinum-based chemotherapy were randomly assigned 1:1 to nivolumab (3 mg/kg once every 2 weeks) or docetaxel (75 mg/m(2) once every 3 weeks) until progression or unacceptable toxicity. The primary end point for both trials was OS; secondary end points included progression-free survival (PFS) and safety. Exploratory landmark analyses were investigated. RESULTS: After the minimum follow-up of 64.2 and 64.5 months for CheckMate 017 and 057, respectively, 50 nivolumab-treated patients and nine docetaxel-treated patients were alive. Five-year pooled OS rates were 13.4% versus 2.6%, respectively; 5-year PFS rates were 8.0% versus 0%, respectively. Nivolumab-treated patients without disease progression at 2 and 3 years had an 82.0% and 93.0% chance of survival, respectively, and a 59.6% and 78.3% chance of remaining progression-free at 5 years, respectively. Treatment-related adverse events (TRAEs) were reported in 8 of 31 (25.8%) nivolumab-treated patients between 3-5 years of follow-up, seven of whom experienced new events; one (3.2%) TRAE was grade 3, and there were no grade 4 TRAEs. CONCLUSION: At 5 years, nivolumab continued to demonstrate a survival benefit versus docetaxel, exhibiting a five-fold increase in OS rate, with no new safety signals. These data represent the first report of 5-year outcomes from randomized phase III trials of a programmed death-1 inhibitor in previously treated, advanced NSCLC.
Notes
1527-7755 Borghaei, Hossein Gettinger, Scott Vokes, Everett E Chow, Laura Q M Burgio, Marco Angelo de Castro Carpeno, Javier Pluzanski, Adam Arrieta, Oscar Frontera, Osvaldo Arén Chiari, Rita Butts, Charles Wójcik-Tomaszewska, Joanna Coudert, Bruno Garassino, Marina Chiara Ready, Neal Felip, Enriqueta García, Miriam Alonso Waterhouse, David Domine, Manuel Barlesi, Fabrice Antonia, Scott Wohlleber, Markus Gerber, David E Czyzewicz, Grzegorz Spigel, David R Crino, Lucio Eberhardt, Wilfried Enst Erich Li, Ang Marimuthu, Sathiya Brahmer, Julie Journal Article United States J Clin Oncol. 2021 Jan 15:JCO2001605. doi: 10.1200/JCO.20.01605.